
    
      To determine whether significant in vivo expansion of auto-ENK cells occurs, defined as a > 4
      fold increase in absolute cluster of differentiation 3(CD3)-cluster of differentiation 56
      (CD56+) NK cell count/blood 7 days after infusion over the pre-study baseline level and the
      safety of the ENK cell therapy in research participants with high-risk asymptomatic multiple
      myeloma (AMM) defined as gene expression profile (GEP) 70 gene score>-0.26.
    
  